Blog
RSS FeedPosted by Michael Wonder on 29 Jul 2020
BioMed Valley Discoveries’ ulixertinib (BVD-523), a first-in-class ERK inhibitor cancer therapy, receives fast track designation and launches Phase II trial in collaboration with Cmed and Strata Oncology
28 July 2020 - BioMed Valley Discoveries announces the receipt of fast track designation from the US FDA for investigation of ...
Posted by Michael Wonder on 04 May 2020
COVID-19: how EMA fast-tracks development support and approval of medicines and vaccines
4 May 2020 - As researchers race to develop vaccines and therapeutics against COVID-19, EMA has published an overview of how ...